NCT03856164View on ClinicalTrials.gov

Tranexamic Acid for Prevention of Hemorrhage in Cesarean Delivery

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

June 17, 2019

Primary Completion Date

January 10, 2020

Study Completion Date

August 31, 2020

Conditions
Post Partum HemorrhageFibrinolysis; HemorrhageBlood Loss
Interventions
DRUG

Tranexamic Acid

Two doses of Tranexamic Acid (1 gram), diluted in 100 cc of normal saline. Administered intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.

DRUG

Placebo

100 mL of normal saline. Administered intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.

Trial Locations (1)

75235

Parkland Hospital, Dallas

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER

NCT03856164 - Tranexamic Acid for Prevention of Hemorrhage in Cesarean Delivery | Biotech Hunter | Biotech Hunter